KRSA
$30.07-6.29%
Korsana Biosciences Inc.Stock · Healthcare
KRSA financial statements
The full income statement, balance sheet, and cash-flow statement for Korsana Biosciences Inc. (KRSA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 2.07M+3.7% | 2.00M | 0.00-100.0% | 297K-92.5% | 3.94M+71.7% | |
| 7.05M+25.2% | 5.63M-56.5% | 13.0M-31.2% | 18.8M-68.1% | 59.1M-29.2% | ||
| Research & development | 959K+235.3% | 286K-81.1% | 1.51M-74.7% | 5.98M-84.1% | 37.6M-33.3% | |
| Selling, general & administrative | 6.09M+14.0% | 5.34M-34.3% | 8.13M-36.8% | 12.9M-37.6% | 20.6M-28.4% | |
| General & administrative | 6.09M+14.0% | 5.34M-34.3% | 8.13M-36.8% | 12.9M-37.6% | 20.6M-28.4% | |
| Restructuring | — | — | -565K+57.4% | -1.33M | — | |
| Operating income | -4.97M-37.1% | -3.63M+72.0% | -13.0M+30.1% | -18.5M+66.4% | -55.2M+32.1% | |
| Other non-operating income | 1.45M+153.1% | 571K+59.5% | 358K+21.8% | 294K+1937.5% | -16.0K-102.7% | |
| Pre-tax income | -3.53M-15.4% | -3.06M+41.9% | -5.26M+88.1% | -44.1M+14.7% | -51.6M+57.8% | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -3.53M-15.4% | -3.06M+41.9% | -5.26M+88.1% | -44.1M+14.7% | -51.6M+33.6% | ||
| Discontinued operations | — | 0.00-100.0% | 7.33M+128.4% | -25.8M | — | |
| -$7.77+8.3% | -$8.47+46.2% | -$15.75+88.9% | -$141.96+23.2% | -$184.80 | ||
| EPS (basic) | -$7.77+8.3% | -$8.47+46.2% | -$15.75+88.9% | -$141.96+23.2% | -$184.80 | |
| Weighted-avg shares (basic) | 454K+26.3% | 360K+7.7% | 334K+7.6% | 310K+11.0% | 280K | |
| Weighted-avg shares (diluted) | 454K+26.3% | 360K+7.7% | 334K+7.6% | 310K+11.0% | 280K | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 4.63M+9.7% | 4.22M-47.3% | 8.02M-45.9% | 14.8M-73.3% | 55.5M-5.2% | ||
| Cash & equivalents | 3.24M+0.2% | 3.23M-57.3% | 7.57M-43.4% | 13.4M-75.2% | 54.0M-0.8% | |
| Accounts receivable | 1.00M+79.9% | 556K | 0.00-100.0% | 96.0K-4.0% | 100K | |
| Prepaid expenses | 384K-8.8% | 421K-4.8% | 442K-45.1% | 805K-13.3% | 928K+13.7% | |
| Other current assets | 11.0K-31.3% | 16.0K+45.5% | 11.0K-98.0% | 537K+14.7% | 468K-85.2% | |
| 9.98M+4.3% | 9.57M-28.4% | 13.4M-26.0% | 18.1M-69.5% | 59.3M-48.6% | ||
| Property, plant & equipment | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 65.0K-99.1% | |
| Operating lease right-of-use | — | — | 0.00-100.0% | 1.22M-13.1% | 1.40M-96.8% | |
| Other non-current assets | — | — | 0.00-100.0% | 2.04M-15.2% | 2.41M-13.2% | |
| 900K+24.1% | 725K-65.2% | 2.09M-72.6% | 7.63M-31.2% | 11.1M-34.6% | ||
| Accounts payable | 508K+30.3% | 390K-67.4% | 1.20M-59.7% | 2.97M+62.5% | 1.83M+59.1% | |
| Short-term & current debt | — | — | — | 3.50M+0.0% | 3.50M+0.0% | |
| Current lease liability | — | — | — | — | 0.00-100.0% | |
| Non-current lease liability | — | — | — | — | 0.00-100.0% | |
| 9.09M+2.7% | 8.85M-21.6% | 11.3M+8.0% | 10.5M-78.3% | 48.2M-18.9% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | — | |
| Common stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Additional paid-in capital | 280M+1.4% | 276M+0.2% | 276M+2.3% | 270M+2.4% | 263M+18.1% | |
| Retained earnings | -271M-1.3% | -267M-1.2% | -264M-2.0% | -259M-20.5% | -215M-31.6% | |
| Accumulated other comprehensive income | — | 0.00+100.0% | -12.0K+40.0% | -20.0K+13.0% | -23.0K+14.8% | |
| Total equity incl. non-controlling | 9.09M+2.7% | 8.85M-21.6% | 11.3M+8.0% | 10.5M | — | |
| Total liabilities & equity | 9.98M+4.3% | 9.57M-28.4% | 13.4M-26.0% | 18.1M-69.5% | 59.3M-48.6% | |
| Common shares issued | 561K+44.8% | 387K+2.5% | 378K+21.6% | 311K+0.3% | 310K+27.5% | |
| Common shares outstanding | 546K+50.1% | 364K+2.9% | 353K+13.7% | 311K+0.3% | 310K+27.5% | |
| Shares outstanding (cover) | 619K+59.8% | 387K+0.0% | 387K+24.5% | 311K+0.3% | 310K+27.5% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -3.31M+23.5% | -4.33M+79.6% | -21.2M+47.7% | -40.6M-11.2% | -36.5M+49.6% | ||
| Depreciation & amortization | — | — | 0.00-100.0% | 65.0K-86.2% | 472K-79.5% | |
| Share-based compensation | 441K-29.4% | 625K-41.4% | 1.07M-82.9% | 6.25M-34.9% | 9.61M-35.9% | |
| Change in receivables | 444K-20.1% | 556K+679.2% | -96.0K-2300.0% | -4.00K-104.0% | 100K | |
| — | 0.00-100.0% | 10.4M | 0.00-100.0% | 1.46M+7994.4% | ||
| Capital expenditure | — | — | — | 0.00-100.0% | 7.00K-99.5% | |
| Free cash flow | — | — | — | -40.6M-11.2% | -36.5M+50.7% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Proceeds from sale of PP&E | — | — | — | 0.00-100.0% | 1.46M-5.1% | |
| 3.32M | 0.00-100.0% | 5.02M+17224.1% | 29.0K-99.9% | 30.8M+9.6% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 1.38M | 0.00-100.0% | 5.00M | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 0.00+100.0% | -6.00K-175.0% | 8.00K+166.7% | 3.00K-25.0% | 4.00K+157.1% | |
| Net change in cash | 8.00K+100.2% | -4.34M+25.3% | -5.81M+85.7% | -40.6M-850.1% | -4.27M+90.4% | |
| Source filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
About this data
Source: KRSA’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all KRSA filings on SEC EDGAR → Not investment advice.